Imperial College London
Alternate

Professor Sir Roy Anderson FRS, FMedSci

Faculty of Medicine, School of Public Health

Professor in Infectious Disease Epidemiology
 
 
 
//

Contact

 

roy.anderson Website

 
 
//

Assistant

 

Mrs Clare Mylchreest +44 (0)7766 331 301

 
//

Location

 

LG35Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{McRae-McKee:2019:10.1016/j.jalz.2019.07.010,
author = {McRae-McKee, K and Chinedu, T and Udeh-Momoh, CT and Price, G and Sumali, Bajaj S and de, Jager CA and Scott, D and Hadjichrysanthou, C and McNaughton, E and Bracoud, L and Ahmadi-Abhari, S and De, Wolf F and Anderson, R and Middleton, L},
doi = {10.1016/j.jalz.2019.07.010},
journal = {Alzheimers & Dementia},
pages = {1348--1356},
title = {Perspective: Clinical relevance of the dichotomous classification of Alzheimer’s disease biomarkers: Should there be a “grey zone”?},
url = {http://dx.doi.org/10.1016/j.jalz.2019.07.010},
volume = {15},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The 2018 National Institute on Aging and the Alzheimer's Association (NIA-AA) research framework recently redefined Alzheimer's disease (AD) as a biological construct, based on in vivo biomarkers reflecting key neuropathologic features. Combinations of normal/abnormal levels of three biomarker categories, based on single thresholds, form the AD signature profile that defines the biological disease state as a continuum, independent of clinical symptomatology. While single thresholds may be useful in defining the biological signature profile, we provide evidence that their use in studies with cognitive outcomes merits further consideration. Using data from the Alzheimer's Disease Neuroimaging Initiative with a focus on cortical amyloid binding, we discuss the limitations of applying the biological definition of disease status as a tool to define the increased likelihood of the onset of the Alzheimer's clinical syndrome and the effects that this may have on trial study design. We also suggest potential research objectives going forward and what the related data requirements would be.
AU  - McRae-McKee,K
AU  - Chinedu,T
AU  - Udeh-Momoh,CT
AU  - Price,G
AU  - Sumali,Bajaj S
AU  - de,Jager CA
AU  - Scott,D
AU  - Hadjichrysanthou,C
AU  - McNaughton,E
AU  - Bracoud,L
AU  - Ahmadi-Abhari,S
AU  - De,Wolf F
AU  - Anderson,R
AU  - Middleton,L
DO  - 10.1016/j.jalz.2019.07.010
EP  - 1356
PY  - 2019///
SN  - 1552-5260
SP  - 1348
TI  - Perspective: Clinical relevance of the dichotomous classification of Alzheimer’s disease biomarkers: Should there be a “grey zone”?
T2  - Alzheimers & Dementia
UR  - http://dx.doi.org/10.1016/j.jalz.2019.07.010
UR  - http://hdl.handle.net/10044/1/74118
VL  - 15
ER  -
Download